[go: up one dir, main page]

MX2012000952A - Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica. - Google Patents

Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica.

Info

Publication number
MX2012000952A
MX2012000952A MX2012000952A MX2012000952A MX2012000952A MX 2012000952 A MX2012000952 A MX 2012000952A MX 2012000952 A MX2012000952 A MX 2012000952A MX 2012000952 A MX2012000952 A MX 2012000952A MX 2012000952 A MX2012000952 A MX 2012000952A
Authority
MX
Mexico
Prior art keywords
weight gain
gain associated
pharmaceutical therapy
predicting weight
predicting
Prior art date
Application number
MX2012000952A
Other languages
English (en)
Inventor
Jennifer Kay Leohr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2012000952A publication Critical patent/MX2012000952A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/207—Diffractometry using detectors, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions
    • G01N23/2076—Diffractometry using detectors, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions for spectrometry, i.e. using an analysing crystal, e.g. for measuring X-ray fluorescence spectrum of a sample with wavelength-dispersion, i.e. WDXFS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Métodos para usar TRL V6 como un biomarcador para el riesgo de ganancia de peso asociada con el tratamiento de un paciente con un agente farmacéutico, como por ejemplo, olanzapina.
MX2012000952A 2009-07-22 2010-07-16 Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica. MX2012000952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27150809P 2009-07-22 2009-07-22
PCT/US2010/042208 WO2011011267A1 (en) 2009-07-22 2010-07-16 Method for predicting weight gain associated with a pharmaceutical therapy

Publications (1)

Publication Number Publication Date
MX2012000952A true MX2012000952A (es) 2012-02-28

Family

ID=42663617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000952A MX2012000952A (es) 2009-07-22 2010-07-16 Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica.

Country Status (12)

Country Link
US (1) US20120108947A1 (es)
EP (1) EP2457098B1 (es)
JP (1) JP5650734B2 (es)
KR (3) KR20120044984A (es)
CN (2) CN104749333A (es)
AU (1) AU2010274140B2 (es)
BR (1) BR112012001271A2 (es)
CA (1) CA2765617A1 (es)
EA (1) EA201270188A1 (es)
ES (1) ES2517268T3 (es)
MX (1) MX2012000952A (es)
WO (1) WO2011011267A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
WO1993003450A1 (en) 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
CN1860989A (zh) * 1998-11-30 2006-11-15 诺沃挪第克公司 医疗系统和患者使用该系统进行自我医疗的控制方法
EP1270012A1 (en) * 2001-06-21 2003-01-02 Pfizer Products Inc. Use of pulmonary administration of insulin for treatment of diabetes
WO2003012416A1 (en) 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
GB0213786D0 (en) * 2002-06-14 2002-07-24 Imp College Innovations Ltd Metabolic phenotyping
AU2003285926A1 (en) 2002-10-25 2004-05-25 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
AU2003286726A1 (en) * 2002-10-25 2004-05-13 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
CA2561536C (en) * 2004-04-01 2017-09-19 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US8518021B2 (en) * 2004-05-27 2013-08-27 Baxter International Inc. Apparatus and method for therapeutic delivery of medication
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
BRPI0821364A2 (pt) * 2007-12-19 2015-06-16 Lilly Co Eli Processos, sistemas e produtos de programa de computador para prever a capacidade de resposta a uma terapia farmacêutica para obesidade ou para avaliação de agentes farmacêuticos para investigação
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法

Also Published As

Publication number Publication date
JP2012533754A (ja) 2012-12-27
CN102472758B (zh) 2015-05-06
AU2010274140B2 (en) 2013-09-26
AU2010274140A1 (en) 2012-01-19
EA201270188A1 (ru) 2012-06-29
BR112012001271A2 (pt) 2016-02-10
ES2517268T3 (es) 2014-11-03
KR20120044984A (ko) 2012-05-08
KR20140040290A (ko) 2014-04-02
CA2765617A1 (en) 2011-01-27
CN104749333A (zh) 2015-07-01
WO2011011267A1 (en) 2011-01-27
EP2457098B1 (en) 2014-08-13
EP2457098A1 (en) 2012-05-30
CN102472758A (zh) 2012-05-23
US20120108947A1 (en) 2012-05-03
KR20160067197A (ko) 2016-06-13
JP5650734B2 (ja) 2015-01-07

Similar Documents

Publication Publication Date Title
AU2019232913A1 (en) Methods and processes for non-invasive assessment of genetic variations
MY168762A (en) Certain chemical entities, compositions and methods
EP3888714B8 (en) Collagenous tissue pocket for an implantable medical device, and manufacturing method therefor
SMT201700605T1 (it) Metodo per la preparzione di tessuti, in particolare di tessuti adiposi
IL210208A0 (en) Systems, devices, and methods for improving accuracy of biosensors using fill time
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
IL217442A0 (en) Methods, systems and devices for performing incremental updates of partial databases
EP4299121A3 (en) Method of using cyclodextrin
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
GB201111870D0 (en) Method and apparatus for measuring the levels of hormones, neuro transmitters, bio markers or the like
PH12015501088A1 (en) Dimeric compounds
MX384662B (es) Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona
MX2013002768A (es) Derivados de desmetil-estradiol sustituido en 6 como agonistas de er-beta selectivos.
IN2013MN00733A (es)
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
MX2012000952A (es) Metodo para pronosticar la ganancia de peso asociada con una terapia farmaceutica.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
PT2807486T (pt) Método para a previsão in vitro, numa amostra sanguínea, da probabilidade de um paciente desenvolver dengue grave
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
EP2595697B8 (fr) Procédé de fabrication d'une électrode à usage médical, et électrode obtenue
UA59700U (ru) Способ лечения метаболического синдрома
WO2011115993A3 (en) Method for determining substance non-toxicity

Legal Events

Date Code Title Description
FG Grant or registration